{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:38:53Z","timestamp":1791848333225,"version":"4.3.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004742","name":"National Academy of Sciences of Ukraine","doi-asserted-by":"publisher","award":["0122U000412"],"award-info":[{"award-number":["0122U000412"]}],"id":[{"id":"10.13039\/501100004742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The effect of renin-angiotensin-aldosterone system (RAAS) inhibitors in combination with COVID-19 and diabetes mellitus (DM) remains unknown. We assessed the risk of death in COVID-19 inpatients based on the presence or absence of DM, arterial hypertension (AH) and the use of RAAS inhibitors or other antihypertensives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The results of treatment of all adult PCR-confirmed COVID-19 inpatients (n = 1097, women 63.9%) from 02\/12\/2020 to 07\/01\/2022 are presented. The presence of DM at the time of admission and the category of antihypertensive drugs during hospital stay were noted. Leaving the hospital due to recovery or death was considered as a treatment outcome. Multivariable logistic regression analysis was used to assess the risk of death. Patients with COVID-19 without AH were considered the reference group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>DM was known in 150 of 1,097 patients with COVID-19 (13.7%). Mortality among DM inpatients was higher: 20.0% <jats:italic>vs<\/jats:italic>. 12.4% respectively (p=0.014). Male gender, age, fasting plasma glucose (FPG) and antihypertensives were independently associated with the risk of dying in patients without DM. In DM group such independent association was confirmed for FPG and treatment of AH. We found a reduction in the risk of death for COVID-19 inpatients without DM, who received RAAS inhibitors compared with the corresponding risk of normotensive inpatients, who did not receive antihypertensives: OR 0.22 (95% CI 0.07\u20130.72) adjusted for age, gender and FPG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This result raises a question about the study of RAAS inhibitors effect in patients with Covid-19 without AH.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1077959","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T09:31:58Z","timestamp":1674120718000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["RAAS inhibitors are associated with a better chance of surviving of inpatients with Covid-19 without a diagnosis of diabetes mellitus, compared with similar patients who did not require antihypertensive therapy or were treated with other antihypertensives"],"prefix":"10.3389","volume":"14","author":[{"given":"Mykola","family":"Khalangot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiia","family":"Sheichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Gurianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Zakharchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Kravchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykola","family":"Tronko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2020.195","article-title":"Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox","volume":"42","author":"Javanmard","year":"2021","journal-title":"Infection Control Hosp Epidemiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.3390\/ijms22105263","article-title":"Circulating soluble ACE2 and upstream microRNA expressions in serum of type 2 diabetes mellitus patients","volume":"22","author":"Elemam","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.725967","article-title":"Regulation of angiotensin-converting enzyme 2: A potential target to prevent COVID-19","volume":"12","author":"Hu","year":"2021","journal-title":"Front Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-00893-5","article-title":"The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19","volume":"45","author":"McFarlane","year":"2022","journal-title":"Hypertension Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e213594","DOI":"10.1001\/jamanetworkopen.2021.3594","article-title":"Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: A systematic review and meta-analysis","volume":"4","author":"Baral","year":"2021","journal-title":"JAMA network Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/15353702211054452","article-title":"Relationship between hyperglycemia, waist circumference, and the course of COVID-19: Mortality risk assessment","volume":"247","author":"Khalangot","year":"2021","journal-title":"Exp Biol Medicine;"},{"key":"B9","unstructured":"STANDARDS OF MEDICAL CARE \"CORONAVIRUS DISEASE (COVID-19)\" ministry of health of Ukraine (Document in Ukrainian)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaa096","article-title":"Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: Results from an Italian cohort of 133 hypertensives","volume":"33","author":"Felice","year":"2020","journal-title":"Am J hypertension"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3390\/jcm9103136","article-title":"Association of hypertension with all-cause mortality among hospitalized patients with COVID-19","volume":"9","author":"Rodilla","year":"2020","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"dc201444","DOI":"10.2337\/figshare.13034210","article-title":"Type 2 diabetes and COVID-19-related mortality in the critical care setting: A national cohort study in England, march-july (2020)","volume":"23","author":"Dennis","year":"2020","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.639222","article-title":"Hypertension and COVID-19: Ongoing controversies","volume":"8","author":"Tadic","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810625","article-title":"Intensive versus conventional glucose control in critically ill patients","volume":"360","year":"2009","journal-title":"New Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"102484","DOI":"10.1016\/j.dsx.2022.102484","article-title":"Association of statin and\/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study","volume":"16","author":"Harris","year":"2022","journal-title":"Diabetes Metab Syndrome: Clin Res Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2021.12.003","article-title":"Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review","volume":"12","author":"Singh","year":"2021","journal-title":"J Pharm Anal"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.917","article-title":"The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment","volume":"10","author":"Lumbers","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1055\/a-1138-0959","article-title":"Effects of ACE inhibitors and angiotensin receptor blockers in normotensive patients with diabetic kidney disease","volume":"52","author":"He","year":"2020","journal-title":"Hormone Metab Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-021-01256-9","article-title":"Sodium-glucose co-transporter 2 inhibitors in COVID-19: Meeting at the crossroads between heart, diabetes and infectious diseases","volume":"43","author":"Koufakis","year":"2021","journal-title":"Int J Clin Pharm"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1077959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T12:19:41Z","timestamp":1674476381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1077959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":21,"alternative-id":["10.3389\/fendo.2023.1077959"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1077959","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"article-number":"1077959"}}